In A Volatile Time, Pharma Reassures Business Remains Steady
Amid a stock market freefall spurred largely by coronavirus uncertainty, big pharma sought to reassure investors and the public that supply disruptions are not an immediate concern and they are monitoring business operations day-by-day.
You may also be interested in...
Q1 Sales & Earnings: An Opportunity For Clarity In An Uncertain Time
Johnson & Johnson is the first big pharmaceutical company to report first quarter financial results, and investors across the industry are interested in hearing how the COVID-19 pandemic is impacting the sector's fundamental business dynamics.
Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest
US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.
For Drugs That Increase Risk Of Infection, More Questions Than Answers In The Coronavirus Era
Autoimmune disease drugs ranging from Humira to Cosentyx to Tremfya to Xeljanz carry warnings about increased risk of infections. This raises new questions in the novel coronavirus outbreak.